Amgen Revenue Growth: 3.44%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMGN Revenue Growth Rankings
| Overall | 38th percentile | 2717 of 4424 |
| Sector | 36th percentile | 293 of 464 in Healthcare |
| Industry | 44th percentile | 70 of 127 in Biotechnology |
AMGN Revenue Growth Range, Past 5 Years
| Minimum | -0.22% | Jun 1989 |
| Maximum | 3605% | Mar 1991 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AMGN related companies
AMGN News
FDA panel of cancer experts voted against use for $AMGN Xgeva in prostate cancer. http://stks.co/2K65
about 3 days ago by abubnic
about 3 days ago by abubnic
$DNDN Analyst Says FDA Panel Rejection on $AMGN XGEVA Would Not Positively Affect DNDN's PROVENGE, as they Are Not Mutually Exclusive
about 4 days ago by Benzinga
about 4 days ago by Benzinga
@GArgondizza Yea need the bio's to come back. currently in 4 of this site's favs $VVUS $ACHN $AMGN $IDIX....bought $SODA earlier bc of $GMCR
about 4 days ago by collegefb81
about 4 days ago by collegefb81
With $AMGN failure of #Xgeva, does this mean they will make a play for $DNDN? Time will tell.
about 4 days ago by skrochta
about 4 days ago by skrochta
Amgen $AMGN fails to win panel backing for expanded Xgeva cancer use; vote was 12-1 against
about 4 days ago by Street_Insider
about 4 days ago by Street_Insider
Amgen (AMGN) fails to win panel backing for expanded Xgeva cancer use -Bloomberg
Feb 08, 12:09PM Street Insider
Feb 08, 12:09PM Street Insider
$DNDN looking weak after breakout on Monday.....sellers exiting before $AMGN FDA news
about 4 days ago by skrochta
about 4 days ago by skrochta
Canaccord Genuity raises $DNDN price target to $18 on low likelihood of $AMGN competitive drug approval. http://stks.co/2IIm
about 5 days ago by abubnic
about 5 days ago by abubnic
Bio's continue to lead & formed bull outside reversal today $IBB $BIB $BIIB $AMGN $CELG $GILD http://chart.ly/qqkeaka
about 6 days ago by TradetheLeaders
about 6 days ago by TradetheLeaders
In 1990 we traded $AMGN at EF Hutton / Lehman and well nobody knew who they were... http://stks.co/2EjE
about 9 days ago by EXPstocktrader
about 9 days ago by EXPstocktrader
$AMGN http://stks.co/2D0f Been moving strongly and breaking out again yesterday; watch over yest high
about 10 days ago by fornix
about 10 days ago by fornix
Biotechs are red hot right now just like around this time last year $ibb, $biib, $amgn $vrtx ect. ect.
about 11 days ago by doomdog144
about 11 days ago by doomdog144
$AMGN http://stks.co/2C9S based on IBB, $BIIB strength, $AMGN looks ready here
about 11 days ago by dangerrangers
about 11 days ago by dangerrangers
$AMGN http://stks.co/28mY Poised to breakout of this Bull Flag after a nice run since 12/21
about 14 days ago by TraderFlorida
about 14 days ago by TraderFlorida
$AMGN http://stks.co/28UC consolidating here in this tight channel. next week could breakout
about 15 days ago by MCM
about 15 days ago by MCM
RT @gtlackey RT @StockTwits RT @adamfeuerstein $AMLN $ALKS halted <-- $AMGN not $AMLN <-- maybe I got bad info
about 16 days ago by gtlackey
about 16 days ago by gtlackey
RT @StockTwits RT @adamfeuerstein $AMLN $ALKS halted <-- $AMGN not $AMLN
about 16 days ago by gtlackey
about 16 days ago by gtlackey
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMGN | 67.36 | 0.52 | 0.78% | 59.04B |
| ALSK | 2.81 | -0.02 | -0.71% | 127.01M |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
| COST | 84.20 | -0.33 | -0.39% | 36.49B |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
| EONC | 1.66 | 0.15 | 9.93% | 4.75M |
| SWHC | 5.16 | -0.10 | -1.90% | 333.39M |
| KERX | 3.20 | -0.10 | -3.03% | 223.04M |
| HTCO | 11.74 | -0.26 | -2.17% | 157.08M |
| GAIA | 3.64 | 0.15 | 4.30% | 84.88M |